SA519410561B1 - عوامل صيدلية، تركيبات، وطرق تتعلق بذلك - Google Patents

عوامل صيدلية، تركيبات، وطرق تتعلق بذلك

Info

Publication number
SA519410561B1
SA519410561B1 SA519410561A SA519410561A SA519410561B1 SA 519410561 B1 SA519410561 B1 SA 519410561B1 SA 519410561 A SA519410561 A SA 519410561A SA 519410561 A SA519410561 A SA 519410561A SA 519410561 B1 SA519410561 B1 SA 519410561B1
Authority
SA
Saudi Arabia
Prior art keywords
compositions
pharmaceutical agents
methods relating
methods
composition
Prior art date
Application number
SA519410561A
Other languages
Arabic (ar)
English (en)
Inventor
ريدي يرامريدي ثيروباثي
لان زي-جيان
باور رونان
يانيكوريس إلكسندروس
Original Assignee
اولتيك، انك.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by اولتيك، انك. filed Critical اولتيك، انك.
Publication of SA519410561B1 publication Critical patent/SA519410561B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/167Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SA519410561A 2017-05-19 2019-11-14 عوامل صيدلية، تركيبات، وطرق تتعلق بذلك SA519410561B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762508730P 2017-05-19 2017-05-19

Publications (1)

Publication Number Publication Date
SA519410561B1 true SA519410561B1 (ar) 2024-03-06

Family

ID=64274560

Family Applications (1)

Application Number Title Priority Date Filing Date
SA519410561A SA519410561B1 (ar) 2017-05-19 2019-11-14 عوامل صيدلية، تركيبات، وطرق تتعلق بذلك

Country Status (11)

Country Link
US (2) US11014954B2 (enExample)
EP (1) EP3624809A4 (enExample)
JP (1) JP7224303B2 (enExample)
CN (2) CN120647702A (enExample)
AU (1) AU2018269403B2 (enExample)
CA (1) CA3061893A1 (enExample)
NZ (1) NZ758538A (enExample)
RU (1) RU2765286C2 (enExample)
SA (1) SA519410561B1 (enExample)
SG (1) SG11201909932YA (enExample)
WO (1) WO2018212980A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120647702A (zh) 2017-05-19 2025-09-16 全技术公司 药剂、组合物及其相关方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002305073A1 (en) * 2001-03-22 2002-10-08 Research Foundation Of The City University Of New York Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
EP1652519A1 (en) 2004-10-28 2006-05-03 Tamie Nasu Seleniferous composition for producing antioxidase in vivo
US20060198906A1 (en) 2005-03-07 2006-09-07 Sami Labs Limited Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease
US20070077238A1 (en) 2005-10-04 2007-04-05 Teo Alex Y Production of organic and inorganic selenium compounds by lactic acid bacteria
ATE497960T1 (de) * 2005-10-13 2011-02-15 Cv Therapeutics Inc A1-adenosinrezeptoragonisten
WO2009032057A2 (en) 2007-08-29 2009-03-12 Adam Lubin Method for the selective therapy of disease
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
RU2663127C2 (ru) 2013-03-15 2018-08-01 Олтек, Инк. Селенсодержащие композиции и их применение для лечения и предотвращения заболеваний или состояний, связанных с митохондриальной дисфункцией
CA2940283C (en) * 2014-03-14 2021-03-30 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
US20160090397A1 (en) 2014-09-30 2016-03-31 Northeastern University Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
CN120647702A (zh) 2017-05-19 2025-09-16 全技术公司 药剂、组合物及其相关方法

Also Published As

Publication number Publication date
CA3061893A1 (en) 2018-11-22
CN120647702A (zh) 2025-09-16
NZ758538A (en) 2025-08-29
CN110545822A (zh) 2019-12-06
AU2018269403B2 (en) 2025-03-27
JP7224303B2 (ja) 2023-02-17
AU2018269403A1 (en) 2019-11-14
RU2019134865A3 (enExample) 2021-06-30
SG11201909932YA (en) 2019-11-28
WO2018212980A1 (en) 2018-11-22
US20200123191A1 (en) 2020-04-23
US11014954B2 (en) 2021-05-25
US11613552B2 (en) 2023-03-28
RU2765286C2 (ru) 2022-01-28
US20210238216A1 (en) 2021-08-05
JP2020520904A (ja) 2020-07-16
EP3624809A1 (en) 2020-03-25
EP3624809A4 (en) 2021-03-03
RU2019134865A (ru) 2021-06-21
BR112019022918A2 (pt) 2020-05-26

Similar Documents

Publication Publication Date Title
AR125320A2 (es) Compuesto cristalino, método de preparación y composición que lo comprende
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
GEP20237506B (en) Pcsk9 antagonist compounds
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
MX374443B (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparacion y composiciones farmaceuticas que los contienen
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
MY196413A (en) Substituted Carbonucleoside Derivatives Useful as Anticancer Agents
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
GEP20207147B (en) Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
PH12016501813A1 (en) 1,3-benzodioxole derivative
GEP201606555B (en) Compounds and compositions for modulating egfr activity
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
PH12020550703A1 (en) Sulfonamide compounds and use thereof
MY192425A (en) Polymorphs
MX2024008964A (es) Analogos de rapamicina y usos de los mismos.
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
MX2020006436A (es) Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
MX2021005533A (es) Trigliceridos mixtos.
MX2020006370A (es) Pirazolopiridina-diamidas, su uso como insecticida y procesos para prepararlas.
PH12022551241A1 (en) Egfr inhibitors
PH12019500822A1 (en) Crystalline forms of eravacycline